search
Back to results

Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer

Primary Purpose

Urinary Bladder Neoplasms

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Radical Cystectomy
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Bladder Neoplasms focused on measuring Bladder Cancer, Radical cystectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age> 18
  • non-metastatic disease
  • fit for both ORC and RARC
  • Patient-selected urinary diversion: ileal conduit

Exclusion Criteria:

  • if not able to speak/understand Danish
  • not able to cooperate for fully informed consent
  • need for extensive concomitant surgery (i.e. nephroureterectomy)
  • prior down staging chemotherapy (prior neoadjuvant chemotherapy accepted)
  • prior radiation therapy
  • prior major extensive abdominal or pelvic surgery
  • prior peritonitis
  • conditions contraindicating extended Trendelenburg's position

Sites / Locations

  • Department of Urology, Rigshospitalet

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Open Radical Cystectomy (ORC)

Robot-assisted Radical Cystectomy (iRARC)

Arm Description

Open radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an iliac conduit urinary diversion is performed.

Robot-assisted radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an intracorporeal iliac conduit urinary diversion is performed.

Outcomes

Primary Outcome Measures

Participants blinded at discharge
Number of patients that was not unblinded at discharge

Secondary Outcome Measures

Length of Stay (LOS)
Duration (days) of primary hospitalization. From the date of admission until the date of discharge from hospital.
Days Alive and Out of Hospital (DAOH)
Number of days alive and out of hospital within 90 days from surgery
30-day complication rate
Complication rate (Clavien-Dindo)
90-day complication rate
Complication rate (Clavien-Dindo)
Readmission rate
Number of readmissions
Quality of Life (QoL): EORTC QLQ-C30
Registration of differences in QoL. European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC QLQ-C30 (scale range 0-100, a higher score indicating better quality of life))
Quality of Life (QoL): EORTC QLQ-BLM30
Registration of differences in QoL. European Organization for Research and Treatment of Cancer quality of life questionnaire for patients with muscle invasive bladder cancer (QLQ-BLM30 (scale range 0-100, a higher score indicating increase in symptom burden)) will be used.
Blood loss
Both estimated as well as calculated/hidden blood loss
Use of opioids
Use of opioids, mg total postoperatively

Full Information

First Posted
May 29, 2019
Last Updated
January 22, 2021
Sponsor
Rigshospitalet, Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT03977831
Brief Title
Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer
Official Title
A Controlled Blinded Randomized Feasibility Study of Open Radical Cystectomy (ORC) Versus Robot-Assisted Radical Cystectomy With Intracorporal Urinary Diversion (iRARC) Under an Enhanced Recovery After Surgery (ERAS) Setup
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
June 6, 2019 (Actual)
Primary Completion Date
November 1, 2020 (Actual)
Study Completion Date
January 20, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of the study to compare two established methods of radical cystectomy (RC) in patients with bladder cancer. The participants will be treated under conditions in alignment with up-to-date guidelines and care. We wish to investigate whether it is feasible to compare the two methods under conditions of the highest methodological quality.
Detailed Description
Radical cystectomy (RC) is a comprehensive surgery including pelvic lymph node dissection and urinary diversion. The surgery is originally performed as an open procedure (ORC) but with advances in technology the procedure is now also offered as a robot-assisted laparoscopic procedure (RARC). It remains questionable if RARC is superior to ORC in terms of surgical outcomes. Several studies have described outcomes following RARC of which most are comparative studies with only five studies being randomized controlled trials (RCTs). Overall, significant differences in operating room time, estimated blood loss, time to flatus and bowel movement as well as use of morphine sulfate equivalents in favor of RARC has been demonstrated with the exception of operating room time. However, no studies have demonstrated a significant reduction in risk of 30- or 90-day complication rates between ORC and RARC. The RCTs have not been blinded, and therefore may be subject to bias in terms of expectations from patients and care providers. Also, in the already conducted RCTs of ORC versus RARC the urinary diversion has been done extracorporally. Today, it is possible to conduct the whole procedure of RARC intracorporally (iRARC), potentially reducing the surgical stress further. Lastly, the previously conducted RCTs have not consequently been managed under an Enhanced Recovery After Surgery (ERAS) setup. Currently, a multicenter study comparing ORC with RARC is recruiting in the United Kingdom in which the patients are treated with iRARC and under an ERAS setup. The present study will compare the two methods blinded for the participants and all health care providers involved in the postoperative care from the time the patient exits the operating room (OR). Blinded studies in surgery are rare but in gastrointestinal surgery, a blinded study of open versus laparoscopic colonic resection has demonstrated to be feasible and thus we believe that such study must be feasible in an RC setting. Participants will be randomized 1:1 to either ORC or RARC. Blinding: The study is blinded for the patient and for the group of nurses and doctors that will be responsible for the postoperative care. The postoperative care will be managed by members of the bladder cancer team other than the operating surgeon, and OR staff will not be involved in the postoperative care. The abdominal wound will be bandaged to hide the wounds from both an open and laparoscopic procedure. The blinding will be maintained until discharge from hospital.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Bladder Neoplasms
Keywords
Bladder Cancer, Radical cystectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Open Radical Cystectomy (ORC)
Arm Type
Active Comparator
Arm Description
Open radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an iliac conduit urinary diversion is performed.
Arm Title
Robot-assisted Radical Cystectomy (iRARC)
Arm Type
Active Comparator
Arm Description
Robot-assisted radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an intracorporeal iliac conduit urinary diversion is performed.
Intervention Type
Procedure
Intervention Name(s)
Radical Cystectomy
Intervention Description
Participants are randomly and blinded assigned
Primary Outcome Measure Information:
Title
Participants blinded at discharge
Description
Number of patients that was not unblinded at discharge
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Length of Stay (LOS)
Description
Duration (days) of primary hospitalization. From the date of admission until the date of discharge from hospital.
Time Frame
12 months
Title
Days Alive and Out of Hospital (DAOH)
Description
Number of days alive and out of hospital within 90 days from surgery
Time Frame
90 days from surgery
Title
30-day complication rate
Description
Complication rate (Clavien-Dindo)
Time Frame
30 days after surgery
Title
90-day complication rate
Description
Complication rate (Clavien-Dindo)
Time Frame
90 days after surgery
Title
Readmission rate
Description
Number of readmissions
Time Frame
90 days after surgery
Title
Quality of Life (QoL): EORTC QLQ-C30
Description
Registration of differences in QoL. European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC QLQ-C30 (scale range 0-100, a higher score indicating better quality of life))
Time Frame
90 days after surgery
Title
Quality of Life (QoL): EORTC QLQ-BLM30
Description
Registration of differences in QoL. European Organization for Research and Treatment of Cancer quality of life questionnaire for patients with muscle invasive bladder cancer (QLQ-BLM30 (scale range 0-100, a higher score indicating increase in symptom burden)) will be used.
Time Frame
90 days after surgery
Title
Blood loss
Description
Both estimated as well as calculated/hidden blood loss
Time Frame
4 days after surgery
Title
Use of opioids
Description
Use of opioids, mg total postoperatively
Time Frame
until diacharge or up to 90 days, whichever comes first

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age> 18 non-metastatic disease fit for both ORC and RARC Patient-selected urinary diversion: ileal conduit Exclusion Criteria: if not able to speak/understand Danish not able to cooperate for fully informed consent need for extensive concomitant surgery (i.e. nephroureterectomy) prior down staging chemotherapy (prior neoadjuvant chemotherapy accepted) prior radiation therapy prior major extensive abdominal or pelvic surgery prior peritonitis conditions contraindicating extended Trendelenburg's position
Facility Information:
Facility Name
Department of Urology, Rigshospitalet
City
Copenhagen
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer

We'll reach out to this number within 24 hrs